Terren Peizer founded Hythiam in 2003. Recognizing that advances in scientific research definitively established alcohol and drug addiction as physiological chronic diseases — not psychological, sociological or personality disorders — Peizer launched Hythiam.
Prior to forming Hythiam, Peizer founded and served as Chairman and CEO of Clearant, Inc., a biotechnology company that is a leader in pathogen inactivation solutions. Peizer has served as President and Vice Chairman of Hollis-Eden Pharmaceuticals and Chairman of the Board of Cray, Inc. — the supercomputing industry leader. He remains the largest beneficial shareholder of Cray, Inc. He also has been among the largest beneficial shareholders and senior executives at several other technology and biotechnology companies.
Peizer has assisted companies with assembling management teams, boards of directors and scientific advisory boards, and formulating business and financial strategies — including investor and public relations and capital formation. Peizer has a background in venture capital, mergers and acquisitions, investing, and corporate finance. He held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert.
Chris Hassan
Senior Executive Vice President
Chris Hassan currently manages Hythiam’s marketing and sales operations. He has over 20 years of healthcare management experience in sales, marketing and strategic and product development positions, and he spent the last eight years focused on the treatment of substance abuse. Prior to joining Hythiam, he was responsible for the founding and development of the commercial team responsible for the U.S. launch of Suboxone™ for opiate dependence. He has also been involved with the development of novel products for the treatment of alcohol and opiate dependence at Drug Abuse Sciences, and has held management positions at Parke-Davis/Pfizer and Bayer pharmaceuticals.
Richard A. Anderson
Senior Executive Vice President
Richard Anderson has more than a decade of experience in business development, strategic planning, and financial management. He has been a Director and the Chief Financial Officer of Clearant, Inc., a biotechnology company, and served as Chief Financial Officer of Intellect Capital Group. Anderson also served as a consultant to various developmental and emerging growth companies. Anderson was with Price Waterhouse accounting firm, most recently as a Director and Founding Member of PriceWaterhouseCoopers Transaction Support Group, where he was involved in operational and financial due diligence, valuations, and structuring for technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara.
Steven A. Kriegsman
Steven A. Kriegsman is president, chief executive officer and a director of CytRx Corporation, a clinical-stage biopharmaceutical company engaged in developing human therapeutic products. He also serves as a director of RXi. He previously served as a director and chairman of Global Genomics from June 2000 until its merger with Global Genomics in July 2002. Mr. Kriegsman is the chairman of the board and founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. He has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Miravant Medical Technologies, and Maxim Pharmaceuticals. Mr. Kriegsman has a B.S. degree with honors from New York University in accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. From June 2003 until February 2008, he served as a director, and he is the former chairman of the audit committee of, Bradley Pharmaceuticals, Inc. In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr. Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, and the Palisades-Malibu YMCA.
Marc G. Cummins
Marc Cummins is a Managing Partner of Catterton Partners, a private equity investor in consumer products and service companies with over $1 billion of assets under management. Prior to joining Catterton in 1988, Mr. Cummins spent fourteen years at Donaldson, Lufkin & Jenrette Securities Corporation where he was Managing Director of the Consumer Products and Specialty Distribution Group, and was also involved in leveraged buyouts, private equity and high yield financings. He currently serves on the boards of several private companies including Case Logic Inc., Floorgraphics Inc., Titan Outdoor, LLC and DoveBid, Inc. Mr. Cummins received a B.A. in Economics, magna cum laude, from Middlebury College, where he was honored as a Middlebury College Scholar and is a member of Phi Beta Kappa. He also received an M.B.A. in Finance with honors from The Wharton School at the University of Pennsylvania.
Dr. Andrea Grubb Barthwell
Dr. Andrea Grubb Barthwell is the former Deputy Director for Demand Reduction of the White House Office of National Drug Control Policy (ONDCP). Prior to joining ONDCP, Barthwell served as President of American Society of Addiction Medicine (ASAM). She has served as President of the Encounter Medical Group in Oak Park, Illinois and as President and Executive Vice President of two major drug treatment providers in Chicago.
Before her recent government service on President Bush's sub-cabinet, she served on the National Advisory Councils of the National Institute on Drug Abuse (NIDA), on the Center for Substance Abuse Treatment and on the Drug Abuse Advisory Committee of the Food and Drug Administration (FDA). Dr. Barthwell received her Bachelor of Arts in Psychology from Wesleyan University in Connecticut and her Doctor of Medicine from University of Michigan Medical School. She did her post-graduate training at University of Chicago and Northwestern University Medical Center.
Jay A .Wolf
Jay A. Wolf is a partner and co-founder of Trinad Capital, an activist hedge fund focused on micro-cap public companies. Mr. Wolf has a broad range of investment and operations experience that includes senior and subordinated debt lending, private equity and venture capital investments, mergers & acquisitions and public equity investments. Prior to his work at Trinad Capital which commenced in 2003, Mr. Wolf served as executive vice president of Corporate Development for Wolf Group Integrated Communications Ltd. where he was responsible for the company’s acquisition program. Mr. Wolf worked at Canadian Corporate Funding, Ltd., a Toronto-based merchant bank as an analyst in the firm’s senior debt department and subsequently for Trillium Growth Capital, the firm’s venture capital fund. Mr. Wolf currently sits on the boards of Mandalay Media, Inc. (MNDL), Optio Software, Inc. (OPTO), Prolink Holdings Corporation (PLKH), Shells Seafood Restaurants (SHLL), Xcorporeal, Inc. (XCR) and NorthStar Systems, Inc. Mr. Wolf is also a member of the board of Governors at Cedars-Sinai Hospital. Mr. Wolf received a BA from Dalhousie University.
